DRUG · Mapped RxNorm record
bicalutamide
Normalized identity: bicalutamide View linked drug · Find medicine records ·
Find other trials using this name
Clinical trial
Radiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
NCT00002874
Study summary
ClinicalTrials.govRadiation Therapy With or Without Bicalutamide for Recurrent pT3N0 Prostate Cancer After Radical Prostatectomy
Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3
Loading study purpose, treatment groups and outcomes…
View the complete registry record, eligibility and contacts at ClinicalTrials.gov
Drugs and interventions used in this trial
3 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
RADIATION · Unmapped registry intervention
radiation therapy
Find medicine records ·
Find other trials using this name
DRUG · Unmapped registry intervention
placebo
Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Advertisement
Conditions
Prostate Cancerverified · MONDO: prostate cancer
Interventions
Sponsors & collaborators
Radiation Therapy Oncology Grouplead sponsor
National Cancer Institute (NCI)collaborator
SWOG Cancer Research Networkcollaborator
NRG Oncologycollaborator
Mapped research locations
PhiladelphiaPennsylvania, United States5BaltimoreMaryland, United States5MilwaukeeWisconsin, United States4MiamiFlorida, United States3ClevelandOhio, United States3PittsburghPennsylvania, United States3IndianapolisIndiana, United States3OmahaNebraska, United States3New OrleansLouisiana, United States3LexingtonKentucky, United States3BostonMassachusetts, United States2Los AngelesCalifornia, United States2
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT00002874 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.